CRISPR put cheap precise control of heredity within reach

1

Curiosity before cure plans

Isaacson shows scientific revolutions often start with fascination for a molecule’s shape, not an institutional plan to treat disease.

Isaacson begins with Doudna as a girl in Hilo whose father left Watson’s book on her bed, pulling her toward biochemistry when few women were steered that way. At Pomona and Harvard she chose RNA over DNA because its varied shapes seemed biologically richer, a taste that later mattered because CRISPR depends on RNA as a guide, not merely a messenger.

Graduate work with Jack Szostak on RNA catalysis and postdoctoral ribozyme research gave her the structural skills the bacterial puzzle would eventually need. Isaacson treats her habit of chasing harder, riskier problems—including crystal structures at Yale—as a pattern, not a roadmap toward gene editing.

He also folds personality into the method: competitive, driven, anxious about being scooped, she kept moving toward structural puzzles nobody yet linked to medicine. The chapter’s claim is that breakthroughs often ride aesthetic obsession long before anyone names a therapy.

In practice: A chance paperback of Watson’s DNA book on a childhood bed, not a funded disease program, set Doudna toward the RNA expertise CRISPR later required.

2

Found in yogurt and salt lakes

CRISPR was a natural bacterial immune system recognized only when unglamorous applied work met pure genomics across labs.

Isaacson stresses that the repeated DNA sequences Mojica noticed in the late 1980s sat in genomes already sequenced many times; nobody knew they stored viral mugshots. Food-industry researchers at Danisco, trying to keep yogurt cultures from viral collapse, helped reveal that the repeats let bacteria recognize and destroy prior invaders.

The insight joined dairy microbiology to salt-loving archaea and basic genomics. Doudna joined around 2006 only after Banfield asked for RNA help; the system was billions of years old and hiding in plain sight.

Isaacson uses this to undercut lone-genius myths. Basic curiosity about spoiled yogurt and extreme microbes, plus talk across fields, produced a world-changing tool decades later—provided someone was paying attention.

In practice: Danisco scientists protecting yogurt bacteria from viruses supplied a key piece of what became gene editing’s core mechanism.

3

Two labs, one scissors

The Doudna–Charpentier partnership turned a bacterial curiosity into programmable molecular scissors through complementary skills, not solo genius.

At a 2011 Puerto Rico conference Doudna met Charpentier, who had been mapping Streptococcus pyogenes and the Cas9 protein plus a second RNA, tracrRNA, that helped guide the cut. Doudna’s structural biology meshed with Charpentier’s microbiology; much of the work ran over Skype between Berkeley and Sweden.

Their 2012 Science paper showed Cas9 could be aimed with one synthetic guide RNA at any chosen DNA sequence in a test tube. Isaacson calls that the conceptual leap: a general-purpose tool, not merely a bacterial defense.

He flags two shadows. The demo was still in a tube, not living cells—a distinction that later fed the patent fight. And the partnership itself frayed under competing credit claims, previewing courtroom and Nobel disputes.

In practice: The 2012 paper’s single synthetic guide RNA reprogramming Cas9 marked the turn from natural curiosity to aimable gene editor.

4

Speed to patent shapes glory

Zhang’s human-cell results and expedited filings show commercial and institutional incentives now write scientific credit as much as lab notebooks do.

Months after the 2012 paper, Zhang at the Broad published CRISPR-Cas9 editing in human and mouse cells—the step medicine needed—and used faster patent review to secure rights ahead of Berkeley’s slower application. Multi-year fights before the U.S. Patent Trial and Appeal Board and in Europe split differently by jurisdiction.

Isaacson refuses a neat priority verdict. The test-tube demo was necessary; making cuts inside a nucleus wrapped in chromatin was a nontrivial further problem. Universities stood to earn huge licensing revenue; Caribou, Intellia, CRISPR Therapeutics, and Editas turned colleagues into competitors.

He treats the scramble as ordinary modern biotech, where speed to patent and speed to publish fuse with speed to therapy. The same dispute later framed the Nobel’s choice to sideline Zhang.

In practice: Zhang’s team paid for expedited patent review and locked core rights while Berkeley’s application still moved slowly.

5

Somatic cure, germline line

CRISPR revives eugenics fears in sharper form because the same cheap precise tool can fix a patient or alter every descendant.

Isaacson links today’s debates to early-twentieth-century U.S. sterilization programs and the racial policies they later influenced, then carefully splits legitimate therapy from trait selection. Somatic edits affect only the patient; germline edits enter the inheritance line—height, intelligence, eye color, or disease risk alike.

He airs both poles: some argue refusing to erase serious inherited disease when the tool exists is itself a moral failure; others warn any germline use opens a market where wealth buys genetic advantage. Disability-rights critics reject the premise that wiping out deafness or Down syndrome is simply progress.

By the late 2010s, CRISPR Therapeutics and Vertex already had trials aimed at beta-thalassemia and sickle cell, so the therapeutic case was no longer hypothetical. That fault line becomes the book’s central ethical stake.

In practice: Trials for sickle cell and beta-thalassemia showed somatic medicine advancing while germline use remained the bright red line.

6

Moratoriums without enforcement

Asilomar-style self-policing proved only as strong as the least scrupulous actor once He Jiankui ignored the consensus and edited human embryos.

In 2015 Doudna and peers ran Napa and Washington summits modeled on the 1975 Asilomar recombinant-DNA meeting, calling for a moratorium on clinical human germline editing while basic research continued. Isaacson shows Doudna uneasy: she had helped unleash a tool already slipping into cheap DIY kits.

Self-regulation needs every lab and country to comply. CRISPR reagents are inexpensive and easy to obtain, unlike nuclear materials, so norms rest on journals refusing rogue papers and scientists policing their own.

He Jiankui, U.S.-trained, disabled CCR5 in embryos to try for HIV resistance, implanted them, and in November 2018 announced twins Lulu and Nana in Hong Kong. Need was weak—safer ways already blocked father-to-child HIV—edits were mosaic, and CCR5 loss may raise other infection risks. China sentenced him in 2019; the technique stayed available. Isaacson reads the episode as proof that norms without teeth fail.

In practice: He’s CCR5-edited twins, announced to expected praise and met with global condemnation, ended the illusion that summit statements could bind every lab.

7

Scissors that also sense

COVID showed the same Cas machinery could become cheap diagnostics, vindicating basic research once dismissed as impractical.

When the pandemic hit in early 2020, Doudna turned her Berkeley lab and the Innovative Genomics Institute toward community testing and CRISPR-based viral detection. Cas enzymes engineered to recognize specific viral RNA sequences, rather than cut DNA, promised rapid tests without full PCR infrastructure.

Mammoth Biosciences, which she co-founded, and Sherlock Biosciences, tied to Zhang’s circle, chased commercial versions. Isaacson’s larger point is that the payoff was never only gene editing narrowly defined.

He also links CRISPR to the parallel maturation of mRNA vaccines, arguing the 2020s opened with a whole molecular-biology toolkit reaching the clinic together.

In practice: Mammoth and Sherlock repurposed Cas detection for COVID tests that aimed to work with less lab heavy lifting than PCR.

8

Prizes tidy messy credit

The 2020 Chemistry Nobel to Doudna and Charpentier alone shows prize rules force a clean story that many in the field still contest.

October 2020 made Doudna and Charpentier the first two women to share a science Nobel without a male co-recipient, vindicating their 2012 conceptual leap. Isaacson is candid that the choice omitted contributors many peers call essential—especially Zhang’s human-cell step and Siksnys in Lithuania, who submitted related findings around the same time.

Nobel caps of three winners force omissions, yet the pick still judges which origin story counts as foundational. Patent rights stayed separately contested in the U.S. and Europe; the medal settled neither history nor money.

Isaacson’s broader claim is that scientific honor and legal ownership answer to different bodies and can diverge for years after the field’s highest prize is handed out.

In practice: Siksnys’s near-simultaneous work and Zhang’s cell-culture advance both sat outside the two-person Nobel narrative.

9

Breakthrough is not equality

Doudna’s rise shows women reached CRISPR’s top ranks by breaking barriers at personal cost, not because the barriers had vanished.

Isaacson closes the biographical thread by recalling how few senior structural-biology labs women led when Doudna began, and how a family friend once told her girls did not become scientists. Credit fights with male collaborators, including public clashes over Charpentier’s account and Broad scientists, sometimes played out along gendered lines in how hard each side pressed claims.

He refuses a simple triumph tale. He presents her as ambitious, occasionally difficult, anxious about scoops, and shaped by decades of proving she belonged in rooms where she was often the only woman. Founding companies and directing a major institute meant learning to wield institutional power she first found uncomfortable.

The same drive that sent her after RNA structure and a transatlantic collaborator also pushed her to testify, found firms, and accept public responsibility for a technology she could not fully control. Progress, in Isaacson’s telling, is real without being proof the underlying problem is solved.

In practice: Being talked out of science as a girl, then later navigating gendered credit disputes, frames her eventual institutional power as hard-won rather than inevitable.